Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 May;20(3):223-5.
doi: 10.1097/ICU.0b013e328329b656.

Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration

V Swetha E Jeganathan  1 , Nitin Verma
Affiliations
Review

Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration

V Swetha E Jeganathan et al. Curr Opin Ophthalmol. 2009 May.

Abstract

Purpose of review: To report the safety and efficacy of intravitreal injections for age-related macular degeneration (AMD).

Recent findings: Injecting antivascular endothelial growth factor drugs into the vitreal cavity brings new hope to many AMD patients. Currently, several antivascular endothelial growth factor drugs such as pegaptanib, ranibizumab, and bevacizumab are used via the intravitreal route for neovascular AMD. However, these injections are not without ocular or systemic complications.

Summary: Review of current literature suggests that intravitreal antivascular endothelial growth factor agents are generally a safe and effective treatment for neovascular AMD for up to 2-3 years. Presently, there is level I evidence to substantiate this conclusion for pegaptanib and ranibizumab, but not bevacizumab.

PubMed Disclaimer

MeSH terms